ISRCTN ISRCTN63098210
DOI https://doi.org/10.1186/ISRCTN63098210
Protocol serial number N/A
Sponsor Institute of Community and Public Health (Palestinian Territory)
Funders Swedish International Development Cooperation Agency (SIDA) (Sweden), Palestine Solidarity Association (PGS) (Sweden)
Submission date
24/01/2011
Registration date
19/05/2011
Last edited
19/05/2011
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Samia Halileh
Scientific

Birzeit University
Po Box 14
Ramallah
-
Palestine, State of

Phone +972 (0)59 965 3889
Email samia@birzeit.edu

Study information

Primary study designInterventional
Study designQuasi experimental non-randomised controlled intervention trial
Secondary study designNon randomised controlled trial
Study type Participant information sheet
Scientific titleQuasi study using two types of iron: a non-randomised controlled intervention trial
Study objectivesThe introduction of ferrous sulphate at 6 months is suboptimal to the introduction of polymaltose complex iron preparation at 4 months in reducing the level of anaemia at 12 months. Iron preparation needs to be introduced earlier, at 4 months not 6 months and polymaltose complex is more palatable and has less gastrointestinal effects compared to ferrous sulphate.
Ethics approval(s)Local Ethics Committee approved on the 1st September 2008
Health condition(s) or problem(s) studiedAnaemia
Intervention1. Ferrous sulphate (control group)
1.1. Dose is 2 mg/kg/day, starting at 6 months of age, giving 3 bottles to last for 3 months for when the next follow up visit is due
1.2. Total duration is 6 months
1.3. Haemoglobin measured at 12 months
2. Iron polymaltose complex (intervention group)
2.1. Dose is 2 mg/kg/day, starting at 4 months of age, giving 2 bottles, 3 bottles and another 3 bottles to coincide with visits at 4, 6, 9 months
2.2. Total duration is 8 months
2.3. Haemoglobin measured at 12 months.
Intervention typeOther
Primary outcome measure(s)

Haemoglobin level at 12 months

Key secondary outcome measure(s)

1. Feeding practices
2. Side effects of iron preparation
3. Compliance information
4. Family history of thalassaemia
4. Measures obtained via interview after the mother has performed the blood test for her child and before the results of the blood test, i.e., before her next visit to the clinic

Completion date31/08/2010

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit4 Months
Upper age limit6 Months
SexAll
Target sample size at registration640
Key inclusion criteriaAll infants attending the 4 and 6 months immunization
Key exclusion criteria1. Already taking iron
2. Pre-term or of low bith weight (only excluded if infants were already taking iron)
3. Mother refused consent
4. Does not have a file at the clinic
Date of first enrolment01/11/2009
Date of final enrolment31/08/2010

Locations

Countries of recruitment

  • Palestine, State of

Study participating centre

Birzeit University
Ramallah
-
Palestine, State of

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes